Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC

Abstract

Non-small cell lung cancer (NSCLC) harboring EGFR mutations presents a significant therapeutic challenge. While osimertinib has shown efficacy, disease progression is inevitable. This article reviews the MARIPOSA-2 study, which evaluated the efficacy and safety of amivantamab plus chemotherapy with or without lazertinib in patients with EGFR-mutant NSCLC progressing on osimertinib. The study demonstrated superior progression-free survival (PFS) for amivantamab-based regimens compared to chemotherapy alone. These findings offer a promising treatment option for patients with limited therapeutic options.  

Introduction

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Identifying EGFR mutations has transformed the treatment landscape, with targeted therapies such as osimertinib offering substantial clinical benefits. However, the emergence of drug resistance is a persistent challenge. Novel therapeutic strategies are urgently needed to address the unmet medical needs of patients with EGFR-mutant NSCLC progressing on osimertinib.  

The MARIPOSA-2 Study: A Game-Changer?

The phase III MARIPOSA-2 study investigated the efficacy and safety of amivantamab plus chemotherapy with or without lazertinib in patients with EGFR-mutant NSCLC who had progressed on osimertinib. The study demonstrated a significant improvement in progression-free survival (PFS) for both amivantamab-based treatment arms compared to chemotherapy alone. These findings suggest that amivantamab-based regimens may represent a new standard of care for patients with this challenging disease.  

Amivantamab: A Dual-Action Therapeutic

Amivantamab is a novel antibody-drug conjugate (ADC) targeting EGFR and MET. By delivering a potent cytotoxic payload directly to cancer cells, amivantamab has demonstrated promising antitumor activity in preclinical and clinical studies. The addition of chemotherapy to amivantamab appears to enhance its efficacy, potentially by overcoming resistance mechanisms.  

Lazertinib: A Potential Synergistic Partner

Lazertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) with potent activity against EGFR-mutant NSCLC. While adding lazertinib to amivantamab did not significantly improve PFS in the MARIPOSA-2 study, further investigation of this combination may be warranted in specific patient populations.  

Implications for Clinical Practice

The results of the MARIPOSA-2 study have significant implications for the management of patients with EGFR-mutant NSCLC progressing on osimertinib. Amivantamab plus chemotherapy represents a valuable treatment option for these patients. However, careful patient selection and consideration of potential toxicities are essential.  

Future Directions

While the MARIPOSA-2 study has provided important insights, further research is needed to optimize the use of amivantamab in combination with other targeted therapies or immunotherapies. Additionally, exploring biomarkers predictive of response to amivantamab-based regimens is essential for personalized treatment decisions.

Conclusion

The MARIPOSA-2 study has demonstrated the clinical benefit of amivantamab plus chemotherapy in patients with EGFR-mutant NSCLC progressing on osimertinib. This represents a significant advancement in the treatment of this challenging disease. Continued research is essential to further optimize therapeutic strategies for these patients

Reference

Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90. doi:10.1016/j.annonc.2023.10.117